logo-loader
viewGenprex, Inc.

Genprex get set to join elite group of companies on the Russell 3000 Index

The addition comes at a time when the biotech firm is preparing to initiate a Phase I/II clinical trial to evaluate its lead drug candidate, Oncoprex, in combination with AstraZeneca’s Tagrisso for the treatment of non-small cell lung cancer

AstraZeneca -
The Russell 3000 index is comprised of the top 3,000 publicly listed companies with the largest market capitalizations on the NASDAQ and New York Stock Exchange

Genprex Inc (NASDAQ:GNPX), the gene therapy company, has said it is set to join the US broad market Russell 3000 Index on June 26.

The Austin-based firm will join an elite group of 3,000 publicly listed companies with the largest market capitalizations on the NASDAQ and New York Stock Exchange.

Inclusion in the Russell 3000 Index increases Genprex’s visibility among institutional investors, money managers and index funds.

READ: Genprex receives $2.5 million from warrant exercises as it moves towards clinical trials

“This inclusion indicates that our leadership in developing gene therapies is resonating with investors,” Genprex CEO Rodney Varner said in a statement.

The addition comes at a time when the biotech firm is preparing to initiate a Phase I/II clinical trial to evaluate its lead drug candidate, Oncoprex, in combination with AstraZeneca’s Tagrisso for the treatment of non-small cell lung cancer (NSCLC).

Genprex is also planning to file an investigational new drug (IND) application to initiate a clinical trial of Oncoprex in combination with Merck’s Keytruda in NSCLC.

“We believe our inclusion in the Russell 3000 Index is yet another significant milestone for us, as it will further increase our exposure with a broader group of institutional investors,” Varner added.

Genprex had more than $23 million in cash on its balance sheet at the end of its first-quarter 2020, which the group said gives it a “substantial runway” to execute on its clinical plans, conduct additional research and development, and cover general corporate expenses.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: Genprex, Inc.

Price: 3.58 USD

NASDAQ:GNPX
Market: NASDAQ
Market Cap: $139.16 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genprex, Inc. named herein, including the promotion by the Company of Genprex, Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Genprex reveals slew of recent milestones as it plans for upcoming clinical...

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner talks to Proactive's Christine Corrado about the Texas-based biotechnology company's most recent updates. Namely, Varner says the firm has approved the generic name quaratusugene ozeplasmid, for its non-small cell lung cancer drug formerly known as...

on 07/02/2020

2 min read